// App-Quantinova.ai

3085 : MANIFEST-2, a Global, Phase 3, Randomized, Double-Blind, Active-Control Study of CPI‑0610 and Ruxolitinib Vs. Placebo and Ruxolitinib in JAK-Inhibitor-Naive Myelofibrosis Patients

Researchers

Presenter

  • John Mascarenhas

Principal Investigators

  • Claire Harrison

  • Katarina Luptakova

  • Jessica Christo

  • Jing Wang

  • Jennifer A Mertz

  • Gozde Colak

  • James Shao

  • Suresh Bobba

  • Patrick Trojer

  • Adrian Senderowicz

  • Jeffrey S Humphrey

  • Srdan Verstovsek

Medical Centers

  • Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai / The Tisch Cancer Institute, New York, NY

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • Constellation Pharmaceuticals, Inc., Cambridge, MA

  • Constellation Pharmaceuticals, CAMBRIDGE, MA

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Essential thrombocythemia

  • Polycythemia vera

  • Myelofibrosis

Biomarkers

  • Janus kinase

  • Red Blood Cells

Drug/Treatment

  • Ruxolitinib phosphate

  • Fedratinib

  • CPI-0610

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved